TrialHuman vaccines & immunotherapeutics2023

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.

Sue Ann Costa Clemens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.